In a collaboration with the partner Schiclone Pharmaceuticals, biopharmaceutical company Y-mabs has been granted priority review by China's National Medical Products Administration (NMPA).
The drug Danyelza, which has received the special status, is for the treatment of neuroblastoma in the bone or bone marrow. The cancer develops in nerve tissue in infants and children. In the US, the drug was approved and fast-tracked by the FDA under the accelerated approval program.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.